Kummar S, Berlin J, Mascarenhas L, van Tilburg CM, Geoerger B, Lassen UN, Schilder RJ, Turpin B, Nanda S, Keating K, Childs BH, Chirila C, Laetsch TW, Hyman DM, Drilon A, Hong DS. Quality of life in adult and pediatric patients with tropomyosin receptor kinase fusion cancer receiving larotrectinib. Curr Probl Cancer. 2021 Dec;45(6):100734. doi: 10.1016/j.currproblcancer.2021.100734
Davis KL, Kaye JA, Masters ET, Iyer S. Real-world outcomes in patients with ALK-positive non-small cell lung cancer treated with crizotinib. Curr Oncol. 2018 Feb;25(1):e40-9. doi: 10.3747/co.25.3723
Montserrat-Capdevila J, Godoy P, Marsal JR, Barbe F. Predictive model of hospital admission for COPD exacerbation. Resp Care. 2015 Sep;60(9):1288-94. doi: 10.4187/respcare.04005